Skip to menu Skip to content Skip to footer
Associate Professor Peter Mollee
Associate Professor

Peter Mollee

Email: 

Overview

Background

Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School.

Having trained in Brisbane and Toronto, Dr Mollee has developed an international reputation studying amyloidosis and the plasma cell dyscrasias. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and is a member of the AACB Monoclonal Gammopathy Working Group and the International Kidney & Monoclonal Gammopathy Research Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) and current Chair of the Australian Amyloidosis Network. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.

Availability

Associate Professor Peter Mollee is:
Available for supervision

Qualifications

  • Masters (Coursework) of Medical Science, University of Newcastle
  • Royal Australasian College of Physicians, Royal Australasian College of Physicians
  • Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia

Research impacts

The research of the Queensland Amyloidosis Centre aims to improved the diagnosis, monitoring and therapy of all types of amyloidosis. The Centre, in collaboration with Pathology Queensland and the Translational Research Institute, developed laser capture macrodisscution and tandem mass spectrometry analysis to accurately diagnosis the type of amyloidosis that patients have and have introuduced this assay into the clinical laboratory. Research to improve the diagnosis and monitoring of this rare disease has also assessed immunoglobulin free light chain assays, bone scintigraphy and novel radionuclide PET tracers. The Queensland Amyloidosis Centre maintains an active clinical trial program in amyloidosis therapies including both investigator-initiated and commercial studies.

Works

Search Professor Peter Mollee’s works on UQ eSpace

321 works between 1997 and 2025

121 - 140 of 321 works

2019

Journal Article

Bilateral amyloidoma of the trigeminal nerve causing a progressive trigeminal neuropathy: An unusual presentation of localised AL amyloidosis involving the peripheral nervous system

Lyons, Alexandra, Schweitzer, Daniel, Robertson, Thomas, Mollee, Peter, Tsahtsarlis, Antonio, Mitchell, Roger and Wong, David (2019). Bilateral amyloidoma of the trigeminal nerve causing a progressive trigeminal neuropathy: An unusual presentation of localised AL amyloidosis involving the peripheral nervous system. Neurology and Neurosurgery, 2 (2). doi: 10.15761/nns.1000124

Bilateral amyloidoma of the trigeminal nerve causing a progressive trigeminal neuropathy: An unusual presentation of localised AL amyloidosis involving the peripheral nervous system

2019

Conference Publication

Development of an individualized, supervised exercise intervention as standard care for patients with Multiple Myeloma

Nicol, Jennifer, Woodrow, Carmel, Burton, Nicola, Hill, Michelle, Skinner, Tina, Mollee, Peter and Nicol, Andrew (2019). Development of an individualized, supervised exercise intervention as standard care for patients with Multiple Myeloma. 17th International Myeloma Workshop, Boston, MA, United States, 12-15 September 2019. New York, United States: Elsevier. doi: 10.1016/j.clml.2019.09.355

Development of an individualized, supervised exercise intervention as standard care for patients with Multiple Myeloma

2019

Journal Article

Correction to: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group (Nature Reviews Nephrology, (2019), 15, 1, (45-59), 10.1038/s41581-018-0077-4)

Leung, Nelson, Bridoux, Frank, Batuman, Vecihi, Chaidos, Aristeidis, Cockwell, Paul, D’Agati, Vivette D., Dispenzieri, Angela, Fervenza, Fernando C., Fermand, Jean- Paul, Gibbs, Simon, Gillmore, Julian D., Herrera, Guillermo A., Jaccard, Arnaud, Jevremovic, Dragan, Kastritis, Efstathios, Kukreti, Vishal, Kyle, Robert A., Lachmann, Helen J., Larsen, Christopher P., Ludwig, Heinz, Markowitz, Glen S., Merlini, Giampaolo, Mollee, Peter, Picken, Maria M., Rajkumar, Vincent S., Royal, Virginie, Sanders, Paul W., Sethi, Sanjeev, Venner, Christopher P. ... Nasr, Samih H. (2019). Correction to: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group (Nature Reviews Nephrology, (2019), 15, 1, (45-59), 10.1038/s41581-018-0077-4). Nature Reviews Nephrology, 15 (2), 121-121. doi: 10.1038/s41581-018-0102-7

Correction to: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group (Nature Reviews Nephrology, (2019), 15, 1, (45-59), 10.1038/s41581-018-0077-4)

2019

Book Chapter

Cast nephropathy

Hutchison, Colin A. and Mollee, Peter (2019). Cast nephropathy. Onco-nephrology. (pp. 59-66.e3) edited by Kevin W. Finkel, Mark A. Perazella and Eric P. Cohen. Amsterdam, Netherlands: Elsevier. doi: 10.1016/B978-0-323-54945-5.00016-3

Cast nephropathy

2019

Journal Article

PI3K-p110δ contributes to antibody responses by macrophages in chronic lymphocytic leukemia

Enya Chen, Yu-Chen, Burgess, Melinda, Mapp, Sally, Mollee, Peter, Gill, Devinder, Blumenthal, Antje and Saunders, Nicholas A. (2019). PI3K-p110δ contributes to antibody responses by macrophages in chronic lymphocytic leukemia. Leukemia, 34 (2), 451-461. doi: 10.1038/s41375-019-0556-z

PI3K-p110δ contributes to antibody responses by macrophages in chronic lymphocytic leukemia

2018

Journal Article

A Comparison of High-Dose Cytarabine during Induction Versus Consolidation Therapy in Newly Diagnosed AML

Schwarer, Anthony P., Butler, Jason, Jackson, Kathryn, Beligaswatte, Ashanka, Martin, Louisa, Kennedy, Glen, Daniela, Zantomio, Lewis, Ian, Hiwase, Devendra, Wight, Joel, He, Simon, Grigg, Andrew, Morris, Kirk, Mollee, Peter and Marlton, Paula (2018). A Comparison of High-Dose Cytarabine during Induction Versus Consolidation Therapy in Newly Diagnosed AML. HemaSphere, 2 (6) e158, 1-8. doi: 10.1097/HS9.0000000000000158

A Comparison of High-Dose Cytarabine during Induction Versus Consolidation Therapy in Newly Diagnosed AML

2018

Journal Article

Response to Letter to the Editor about immunochemical measurement of urine free light chains

Tate, Jillian R. and Mollee, Peter (2018). Response to Letter to the Editor about immunochemical measurement of urine free light chains. Clinical Chemistry and Laboratory Medicine, 57 (2), e3-e4. doi: 10.1515/cclm-2018-1082

Response to Letter to the Editor about immunochemical measurement of urine free light chains

2018

Journal Article

Immunosuppression is associated with clinical features and relapse risk of B cell posttransplant lymphoproliferative disorder: a retrospective analysis based on the prospective, international, multicenter PTLD-1 trials

Zimmermann, Heiner, Babel, Nina, Dierickx, Daan, Morschhauser, Franck, Mollee, Peter, Zaucha, Jan M., Dreyling, Martin H., Dührsen, Ulrich, Reinke, Petra, Verhoef, Gregor, Subklewe, Marion, Hüttmann, Andreas, Tousseyn, Thomas, Bachy, Emmanuel, Hauser, Ingeborg A., Tarella, Corrado, Van Den Neste, Eric, Gheysens, Olivier, Anagnostopoulos, Ioannis, Leblond, Veronique, Riess, Hanno, Choquet, Sylvain and Trappe, Ralf U. (2018). Immunosuppression is associated with clinical features and relapse risk of B cell posttransplant lymphoproliferative disorder: a retrospective analysis based on the prospective, international, multicenter PTLD-1 trials. Transplantation, 102 (11), 1914-1923. doi: 10.1097/TP.0000000000002269

Immunosuppression is associated with clinical features and relapse risk of B cell posttransplant lymphoproliferative disorder: a retrospective analysis based on the prospective, international, multicenter PTLD-1 trials

2018

Journal Article

Pomalidomide – author reply

Scott, Ashleigh P. and Mollee, Peter (2018). Pomalidomide – author reply. Leukemia and Lymphoma, 60 (4), 1-1. doi: 10.1080/10428194.2018.1516884

Pomalidomide – author reply

2018

Journal Article

Relative survival of patients with lymphoma in Queensland according to histological subtype

Wright, Fraser, Hapgood, Greg, Loganathan, Aravi, Dunn, Nathan, Philpot, Shoni, Moore, Julie and Mollee, Peter (2018). Relative survival of patients with lymphoma in Queensland according to histological subtype. Medical Journal of Australia, 209 (4), 166-172. doi: 10.5694/mja17.00937

Relative survival of patients with lymphoma in Queensland according to histological subtype

2018

Journal Article

Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma

Quach, Hang, Benson, Simon, Haysom, Helen, Wilkes, Anne-Marie, Zacher, Nicole, Cole-Sinclair, Merrole, Miles Prince, Henry, Mollee, Peter, Spencer, Andrew, Joy Ho, Phoebe, Harrison, Simon J, Lee, Cindy, Augustson, Bradley and Daly, James (2018). Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma. Internal Medicine Journal, 48 (2), 210-220. doi: 10.1111/imj.13707

Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma

2018

Conference Publication

The Tumour Microenvironment as an Independent Prognostic Biomarker in Follicular Lymphoma

Tobin, J., Keane, C., Mollee, P., Birch, S., Gould, C., Gunawardana, J., Hoang, T., Savarimuthu, S., Ma, T., Li, L., Murigneux, V. , Fink, L., Matigian, N. and Gandhi, M. K. (2018). The Tumour Microenvironment as an Independent Prognostic Biomarker in Follicular Lymphoma. RACP Congress 2018, Disruption for Healthy Futures, Sydney, NSW Australia, 14–16 May 2018. Hoboken, NJ United States: Wiley. doi: 10.1111/imj.2_13826

The Tumour Microenvironment as an Independent Prognostic Biomarker in Follicular Lymphoma

2018

Conference Publication

Activation of Fc Gamma Receptor-Dependent Responses to Therapeutic Antibodies By Nurse like Cells Requires PI3Kdelta

Chen, Yu-Chen Enya, Burgess, Melinda Lea, Blumenthal, Antje, Mapp, Sally, Mollee, Peter, Gill, Devinder and Saunders, Nicholas Andrew (2018). Activation of Fc Gamma Receptor-Dependent Responses to Therapeutic Antibodies By Nurse like Cells Requires PI3Kdelta. 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA United States, 1-4 December 2018. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2018-99-109719

Activation of Fc Gamma Receptor-Dependent Responses to Therapeutic Antibodies By Nurse like Cells Requires PI3Kdelta

2018

Conference Publication

Perspectives on physical activity of clinical haematologists and their patients with multiple myeloma

Nicol, Jennifer L., Burton, Nicola W., Woodrow, Carmel, Mollee, Peter, Hill, Michelle M., Nicol, Andrew J. and Skinner, Tina L. (2018). Perspectives on physical activity of clinical haematologists and their patients with multiple myeloma. COSA's 45th Annual Scientific Meeting, Mesothelioma and Gastro‐Intestinal Cancers: Technology and Genomics, Perth, Western Australia, 13–15 November 2018. Hoboken, NJ United States: Wiley.

Perspectives on physical activity of clinical haematologists and their patients with multiple myeloma

2017

Conference Publication

The tumor microenvironment is independently prognostic of conventional and clinicogenetic risk models in follicular lymphoma

Tobin, Joshua W. D., Keane, Colm, Mollee, Peter, Birch, Simone, Gould, Clare, Gunawardana, Jay, Hoang, Thanh, Ma, Ti, Abro, Emad Uddin, Shanavas, Mohamed, Yoo, Hyung, Li, Li, Scuffham, Paul, Murigneux, Valentine, Fink, Lynn, Matigian, Nicholas, Vari, Frank, Francis, Santiyagu and Gandhi, Maher K. (2017). The tumor microenvironment is independently prognostic of conventional and clinicogenetic risk models in follicular lymphoma. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.V130.Suppl_1.728.728

The tumor microenvironment is independently prognostic of conventional and clinicogenetic risk models in follicular lymphoma

2017

Journal Article

A global call to arms for clinical laboratories - Harmonised quantification and reporting of monoclonal proteins

Tate, Jillian R., Keren, David F. and Mollee, Peter (2017). A global call to arms for clinical laboratories - Harmonised quantification and reporting of monoclonal proteins. Clinical Biochemistry, 51, 4-9. doi: 10.1016/j.clinbiochem.2017.11.009

A global call to arms for clinical laboratories - Harmonised quantification and reporting of monoclonal proteins

2017

Journal Article

The treatment of paraprotein-related kidney disease

Hutchison, Colin A., Xiong, Fei and Mollee, Peter (2017). The treatment of paraprotein-related kidney disease. Current Opinion in Nephrology and Hypertension, 26 (6), 477-483. doi: 10.1097/MNH.0000000000000369

The treatment of paraprotein-related kidney disease

2017

Journal Article

‘Real-world’ Australian experience of pomalidomide for relapsed and refractory myeloma

Scott, Ashleigh, Weber, Nicholas, Tiley, Campbell, Taylor, Kerry, Taper, John, Harrison, Simon, Chan, Kah-Lok, Stark, Richard, Lee, Cindy, Morris, Kirk, Ho, P. Joy, Dodds, Anthony, Ramanathan, Sundra, Ramakrishna, Raj, Watson, Anne-Marie, Auguston, Bradley, Kwok, Fiona, Quach, Hang, Warburton, Pauline, Rowlings, Philip and Mollee, Peter (2017). ‘Real-world’ Australian experience of pomalidomide for relapsed and refractory myeloma. Leukemia and Lymphoma, 59 (6), 1514-1516. doi: 10.1080/10428194.2017.1387911

‘Real-world’ Australian experience of pomalidomide for relapsed and refractory myeloma

2017

Journal Article

Bisphosphonate guidelines for treatment and prevention of myeloma bone disease

Lee, Oi Lin, Horvath, Noemi, Lee, Cindy, Joshua, Doug, Ho, Joy, Szer, Jeff, Quach, Hang, Spencer, Andrew, Harrison, Simon, Mollee, Peter, Roberts, Andrew W., Talaulikar, Dipti, Brown, Ross, Augustson, Bradley, Ling, Silvia, Jaksic, Wilfrid, Gibson, John, Kalff, Anna, Johnston, Anna, Kalro, Akash, Ward, Chris, Prince, H. Miles and Zannettino, Andrew (2017). Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Internal Medicine Journal, 47 (8), 938-951. doi: 10.1111/imj.13502

Bisphosphonate guidelines for treatment and prevention of myeloma bone disease

2017

Journal Article

The duality of macrophage function in Chronic Lymphocytic Leukaemia

Chen, Y. C. E., Mapp, S., Blumenthal, A., Burgess, M. L., Mazzieri, R., Mattarollo, S., Mollee, P., Gill, D. and Saunders, N. A. (2017). The duality of macrophage function in Chronic Lymphocytic Leukaemia. Biochimica et Biophysica Acta (BBA) Reviews on Cancer, 1868 (1), 176-182. doi: 10.1016/j.bbcan.2017.03.006

The duality of macrophage function in Chronic Lymphocytic Leukaemia

Supervision

Availability

Associate Professor Peter Mollee is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Media

Enquiries

For media enquiries about Associate Professor Peter Mollee's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au